...Davide Imberti; Domenico Prisco Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and mortality in patients undergoing major orthopedic surgery, and routine thromboprophylaxis has been the standard of care over the last 20 years...

... to in the content or advertisements. Cancer Low-molecular-weight heparins Venous thromboembolism Ilirm osliisis Haemostasis 1997;27(suppl I):32 37 A.K. Kakkar R.C.N. Williamson Department of Surgery, Imperial College School o f Medicine, London, UK Prevention of Venous Thromboembolism in Cancer Using Low...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Venous thromboembolism Necropsy Venography H a kinoKta«i« Original Paper Haemostasis...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Heparin, low molecular weight Heparin, standard Warfarin Venous thromboembolism Deep venous thrombosis Pulmonary embolism Haemostasis 1993;23(suppl 1):2 9 Russell D...

... of several studies have indicated that mild hyperhomocysteinemia is common in occlusive arterial disease, no similar studies have been made on venous thromboembolism. In this study of subjects under 50 years of age, we found no significant differences in the plasma homocysteine concentrations, either...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Heparin Lipoprotein lipase Lecithinase Platelet function factor X Venous thromboembolism Oral contraceptives...

..., instructions or products referred to in the content or advertisements. Venous thromboembolism Cancer Microparticles Tissue factor Pathophysiol Haemost Thromb 2007 08;36:177 183 DOI: 10.1159/000175155 Microparticles and Cancer Chirag Amin Nigel Mackman Nigel S. Key Department of Medicine and Program...

... carriers of FVL suffer thrombosis and therefore we sought to determine if the test for ETP could be modified in such a way as to enable detection of FVL patients who were at increased risk of venous thromboembolism. Protac, an activator of both protein C and factor V, was incorporated into the traditional...

...Davide Imberti; Matteo Giorgi Pierfranceschi; Michela Falciani; Domenico Prisco Several epidemiological studies have shown a high prevalence of venous thromboembolism (VTE) complications in patients with acute heart failure; in addition, the level of risk associated with this disease is notable...

...Davide Imberti; Walter Ageno Background: Venous thromboembolism (VTE) is a common life-threatening complication of major trauma. Although clinical guidelines clearly suggest routine VTE prevention with low-molecular-weight heparin (LMWH) in this specific group of patients, there is still a lack...

... receptor activator peptide 6. In conclusion, the expression of CD62 and CD63 of resting and in vitro activated platelets could not be established as a risk factor for spontaneous venous thromboembolism. 11 01 2005 21 03 2005 18 11 2005 © 2005 S. Karger AG, Basel 2005 Copyright...

... anticoagulants (OA) in the prevention of recurrent venous thromboembolism (VTE). Materials and Methods: Computerized searches of Medline and Embase were performed; clinical trials were also located through colleagues and hand scanning of meeting proceedings. Eligibility of the studies and extraction of data were...

...Per Lindmarker Studies have shown subcutaneous low- molecular-weight heparin (LMWH) to be at least as safe and efficacious as intravenous unfractionated heparin (UFH) for the treatment of venous thromboembolism (VTE). Furthermore, unlike UFH, LMWH is administered on a once- or twice-daily basis...

.... Laaban Department of Pneumology and Intensive Care, Hôtel-Dieu Hospital, Paris, France Key Words Pulmonary embolism W Venous thromboembolism W Heparin W Thrombolytic W Thoracic computed tomodensitometry W Lung scintigraphy Abstract Various techniques are available for the diagnosis of pulmonary embolism...

...Sam Schulman Studies have shown that in most patients with venous thromboembolism (VTE), continuation of treatment with vitamin K antagonists for up to 27 months significantly reduces the probability of recurrence. Likewise, prolongation of oral anticoagulation beyond 6 months is believed...

...Susanne M. Smorenburg; Barbara A. Hutten; Martin H. Prins Patients with malignant disease constitute a significant subgroup among patients with venous thromboembolism. Current results suggest that cancer patients are not only at an increased risk for thromboembolic events, particularly during...

...Russell D. Hull; Graham F. Pineo The recently reported reductions in the incidence of post-operative venous thromboembolism (VTE) are related to the widespread use of prophylactic anticoagulants. Many uncertainties remain with regard to the most effective ways to use thromboprophylaxis, however...

...P.M.M. Bossuyt; A.G.M. van den Belt; M.H. Prins Low-molecular-weight heparin has been recommended as the initial treatment of choice for patients with venous thromboembolism who require anticoagulant therapy. In recent studies, outpatient management of these patients has been proposed...

... months of warfarin treatment) in patients with acute proximal deep vein thrombosis. In the LMWH-treated group, the cost incurred for 100 patients was $399,403 (Canadian) or $335,687 (US) with a frequency of objectively documented recurrent venous thromboembolism of 2.8%. In the intravenous heparin...

...Sam Schulman Warfarin remains the standard drug for secondary prophylaxis following venous thromboembolism, however this treatment is not ideal. In patients for whom monitoring is problematic or who have a high risk of bleeding complications, other possible solutions have been explored...